

Hybrigenics asked for trading suspension

Paris, France, on October 19th, 2018 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Euronext Growth market of Euronext Paris, with a focus on research and development of new anticancer treatments, today announces having asked Euronext to suspend the trading of its shares (FR0004153930) until the publication of a press release.

The result of an interim futility analysis of the ongoing double-blind placebo-controlled clinical Phase II study of inecalcitol in acute myeloid leukemia will be published prior to the resumption of the trading.

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical group listed (ALHYG) on the Euronext Growth market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer.

Hybrigenics' development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere[®], the current gold-standard chemotherapeutic treatment for this indication. Inecalcitol has also been tested in two pilot clinical Phase II studies in chronic myeloid leukemia and chronic lymphocytic leukemia and an international double-blind placebo-controlled Phase II studies of inecalcitol is currently ongoing in acute myeloid leukemia. Inecalcitol has received orphan drug designation for chronic lymphocytic leukemia and acute myeloid leukemia in Europe and the United States.

Hybrigenics' research program is exploring the role of enzymes called Ubiquitin-Specific Proteases (USP) in the balance between degradation and recycling of proteins called onco-proteins due to their involvement in various cancers. Hybrigenics is evaluating the interest of inhibitors of USP as anti-cancer drug candidates. Hybrigenics has collaborated with Servier on one particular USP in oncology. In this R&D program, two milestones have been reached and additional milestones may be achieved until registration of a potential drug.

Hybrigenics Pharma Inc., based in Cambridge, Mass., is the U.S. subsidiary of Hybrigenics.

Hybrigenics is listed on the Euronext Growth market of Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG



Hybrigenics

Rémi Delansorne

CEO

Tel.: +33 (0)1 58 10 38 00

investors@hybrigenics.com

NewCap

Financial communication

Pierre Laurent / Mathilde Bohin

Tel.: +33 (0)1 44 71 94 94

hybrigenics@newcap.eu